Reactivos e instrumentos para inmunología, biología celular y biología molecular.
 
> ML-210 [1360705-96-9]

ML-210 [1360705-96-9]

Imprimir Imprimir
Por favor conéctese

Referencia HY-100003-10mg

embalaje : 10mg

Marca : MedChemExpress

Solicitar más información

Contact local distributor :


Teléfono : +1 850 650 7790

ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

ML-210 Estructura química

ML-210 Estructura química

No. CAS : 1360705-96-9

This product is a controlled substance and not for sale in your territory.

Based on 11 publication(s) in Google Scholar

Descripciòn

ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity[1][2].

IC50 & Target

Glutathione Peroxidase 4 (GPX4)[1]
Cellular Effect
Cell Line Type Value Description References
BJ IC50
107 nM
Compound: 2y
Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay
Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay
[PMID: 22297109]
HCT-116 IC50
> 1 μM
Compound: ML-210
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
HeLa IC50
0.253 μM
Compound: ML-210
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
HT-1080 IC50
0.022 μM
Compound: ML-210
Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
MCF7 IC50
> 20 μM
Compound: ML210
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs in presence of Fer-1 by CCK8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs in presence of Fer-1 by CCK8 assay
[PMID: 33725632]
MCF7 IC50
0.076 μM
Compound: ML210
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
[PMID: 33725632]
MDA-MB-231 IC50
0.02 μM
Compound: ML-210
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
MDA-MB-468 IC50
0.066 μM
Compound: ML-210
Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
MEF IC50
0.016 μM
Compound: ML-210
Cytotoxicity against mouse MEF cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against mouse MEF cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
NCI-H522 IC50
0.044 μM
Compound: ML-210
Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
NCI-H522 IC50
34.515 μM
Compound: ML-210
Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days in presence of ferroptosis inhibitor, liproxstatin-1 by methylene blue staining based analysis
Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days in presence of ferroptosis inhibitor, liproxstatin-1 by methylene blue staining based analysis
[PMID: 35984756]
U2OS IC50
0.822 μM
Compound: ML-210
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
WI-38 IC50
0.06 μM
Compound: ML-210
Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis
[PMID: 35984756]
In Vitro

ML-210 exhibits cell-killing activity across a panel of 821 cancer cell lines (WM88, LOX-IMVI, CJM, U257, CAKI2, A498, HT1080, MC38, PANC02). ML-210 is a prodrug that requires cellular activation to bind GPX4[1].
ML-210 has IC50s of 71 nM, 272 nM and 107nM for BJeLR (HRASV12), BJeH-LT (without HRASV12) and DRD cell lines, respectively[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ML-210 Related Antibodies
Peso molecular

475.32

Fòrmula

C22H20Cl2N4O4
No. CAS

1360705-96-9
Appearance

Solid

Color

White to light yellow

SMILES

O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)C4=NOC(C)=C4[N+]([O-])=O
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvente y solubilidad
In Vitro: 

DMSO : 25 mg/mL (52.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1038 mL 10.5192 mL 21.0385 mL
5 mM 0.4208 mL 2.1038 mL 4.2077 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Calculadora de molaridad

  • Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (5.26 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.08 mg/mL (4.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación

Purity: 99.87%

SDS (392 KB)

COA (251 KB) LCMS (264 KB)

Instrucciones de manejo (2659 KB)
Referencias

  • [1]. John K. Eaton, et al. Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors. Biorxiv. 2018.

    [2]. Weïwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6.  [Content Brief]

  • [1]. John K. Eaton, et al. Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors. Biorxiv. 2018.

    [2]. Weïwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1038 mL 10.5192 mL 21.0385 mL 52.5961 mL
5 mM 0.4208 mL 2.1038 mL 4.2077 mL 10.5192 mL
10 mM 0.2104 mL 1.0519 mL 2.1038 mL 5.2596 mL
15 mM 0.1403 mL 0.7013 mL 1.4026 mL 3.5064 mL
20 mM 0.1052 mL 0.5260 mL 1.0519 mL 2.6298 mL
25 mM 0.0842 mL 0.4208 mL 0.8415 mL 2.1038 mL
30 mM 0.0701 mL 0.3506 mL 0.7013 mL 1.7532 mL
40 mM 0.0526 mL 0.2630 mL 0.5260 mL 1.3149 mL
50 mM 0.0421 mL 0.2104 mL 0.4208 mL 1.0519 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ML-210 Related Classifications

  • Apoptosis Metabolic Enzyme/Protease
  • Glutathione Peroxidase Ferroptosis
Help & FAQs

Keywords:

ML-2101360705-96-9ML210ML 210Glutathione PeroxidaseFerroptosisCovalentglutathioneperoxidaseGPX4selenocysteineresidueanti-cancerInhibitorinhibitorinhibit

Usted podría estar interesado también en los siguientes productos:



Referencia
Descripción
Cond.
Precio Sin IVA
HY-15760-10mg
Necrostatin-1 [4311-88-0]
 10mg 
HY-15763-10mg
Erastin [571203-78-6]
 1mg*10